KUMULUS-VAPE
28.5.2019 05:59:06 CEST | Business Wire | Press release
At 11.30 am this Tuesday, May 28 2019, shares in Kumulus Vape (ISIN: FR0013419876 - symbol: MLVAP) will be listed for the first time on the Euronext Access™ market in Paris (by technical admission). Kumulus Vape is an e-merchant specializing in the sale of electronic cigarettes and related 'vaping' products (equipment, e-liquids and accessories).
The listing on the Paris stock exchange is a first for European vape companies, marking a new milestone in the performance trajectory of the company from Lyon, a pioneer in its market in an active phase of development. The aim of this move is to enable Kumulus Vape to raise brand awareness and strengthen its presence on the domestic market.
55,000 shares will be offered for sale on the first day of market trading. This admission to the Euronext Access™ market constitutes a first step, prior to a possible transfer of Kumulus Vape shares to the Euronext Growth® market. The company seeks to introduce a dynamic of shares changing hands that could account for between 5 and 10% of the capital.
Established in 2012, Kumulus Vape is one of the main French online sites for the sale of vaping products (equipment, e-liquid, DIY1 ). With its broad range, comprising over 6,000 items, it offers products for both 'beginners' and vaping experts. As a committed player in combating tobacco and an advocate for the vaping sector, Kumulus Vape offers an unequalled choice of high-performing vaping products at low prices.
In 2018, Kumulus Vape's turnover was €6.5 million, up 116% on 2017. The EBITDA exceeded the €400,000 mark (+128% on 2017), with a net income of nearly €300,000 (+106%). In the first quarter of 2019, turnover rose by 96% to €2.3 million.
Kumulus Vape has a clear aim: to become one of the French leaders in 100% e-commerce vaping in the next three years.
Operating procedures
Listing market:
Euronext Access™
ISIN
:
FR0013419876
Symbol
: MLVAP
Registration procedure
:
technical admission
Number of shares in company capital
:
1,988,000
Number of shares sold on the day of listing
: 55,000
Sale
price per share
: €2.12
Valuation at time of listing
:
€4,214,560
Start of trading
: May 28, 2019
Eligible
for PEA (equity savings plan) and SME PEA
: yes
The operation does not require authorization from the French Financial Markets Authority (AMF). The information document has therefore not been approved by the AMF. The information document is available free of charge from the head office of Kumulus Vape. It may be downloaded from www.kumulusvape.fr/investisseurs . Please note that companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Instead, they are subject to a smaller set of rules that is suitable for small businesses experiencing growth. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company on the regulated market.
Partners in the operation
|
Atout Capital |
Consultant and listing sponsor |
|
|
Lamy Lexel |
Legal advice |
|
|
Mazars |
Auditors |
|
|
Actifin |
Financial communications |
|
About Kumulus Vape
Established in 2012, Kumulus Vape is one of the leading French distributors of e-cigarettes and e-liquids . With www.kumulusvape.fr , its website for individuals, and its wholesale business for specialist boutiques, the Company is positioned on both the B2C and B2B markets. Kumulus Vape's turnover rose to €6.5 million in 2018, representing a growth of 116% on 2017. Kumulus Vape is based in Corbas, just a few minutes from the south of Lyon, and currently has about 25 employees.
1 Do It Yourself: e-liquid base that people can use to create their own blends
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005309/en/
Contact:
KUMULUS VAPE Director of Communications Vincent Baudoin v.baudoin@kumulusvape.fr Tel.: 06 10 84 52 59
ACTIFIN Press relations Aminata Doucouré adoucoure@actifin.fr Tel.: 01 56 88 11 23
ACTIFIN Financial communications Julien Mouret jmouret@actifin.fr Tel.: 01 56 88 11 14
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom